Tumor Immunity and Immunotherapy

Andrew Lichtman, MD PhD
Department of Pathology
Brigham and Women’s Hospital
& Harvard Medical School
Outline

• Tumor antigens
• Immune responses to tumors and anti-tumor effector mechanisms
• Tumor evasion of immune system
• Cancer immunotherapy
  • Checkpoint blockade
  • Adoptive cellular therapy
  • Personalized vaccines
  • Antibody-based therapies
Tumor Immunity: General principles

• The immune system recognizes and reacts against cancers

• The immune response against tumors is often dominated by regulation or tolerance
  • Evasion of host immunity is one of the hallmarks of cancer (Hanahan and Weinberg Cell 144:646, 2011)

• Some immune responses promote cancer growth

• Defining the immune response against cancers will help in developing new immunotherapies
T lymphocytes infiltration of tumors improves prognosis


CD3 Stain


Meta analysis of 124 studies of correlation of T cell subsets and prognosis of 20 cancer types

Abbas, Lichtman, Pillai Cellular and Molecular Immunology. Elsevier 2021

Rodent Work in Tumor Immunology Established Importance of T Cells

Chemical carcinogen induced tumors

Spontaneous tumors in aged mice
Patients’ T cells Respond to Unmutated Proteins Expressed by Tumor

Most tumor antigens that elicit immune responses are neoantigens generated by random passenger mutations (not related to oncogenesis, but are result of genomic instability due to mutations of other genes in cancer cells).
Steps in the Generation of an Anti-Tumor CD8⁺ T Cell Response

Inefficient migration of effector T cells into tumors may impair anti-tumor responses to common cancers.

Cell injury/death at tumor site will generate DAMPs that activate DCs.

CD4+ T cell responses will also occur; most evidence indicates CTLs are the most important effectors.

Abbas, Lichtman, Pillai. Cellular and Molecular Immunology. Elsevier. 2017
Cross-Presentation of Tumor Antigens

Allows DCs to initiate CD8+ T cell responses to tumor antigens
Evasion of the Immune System is a Hallmark of Cancer

Tumors Have Many Ways of Evading the Immune System

Production of immunosuppressive proteins or expression of inhibitory cell surface proteins
- Inhibitory ligand (e.g., PD-L1)
- Inhibitory receptor (e.g., PD-1)
- Immunosuppressive cytokines (e.g., TGF-β)

Inhibition of T cell activation

Immunosuppressive tumor microenvironment
- Treg
- Th1
- MDSC
- CTL

Inhibition of T cell activation and differentiation into Th1 and CTL

Failure to produce tumor antigen
- Lack of T cell recognition of tumor
- Antigen-loss variant of tumor cell

Failure to present tumor antigens
- Class I MHC-deficient tumor cell
- Lack of T cell recognition of tumor

Abbas, Lichtman, Pillai. Cellular and Molecular Immunology. Elsevier. 2021
Generation of Exhausted T cells and Prevention

CD8 + T cell → Stem-like precursor of $T_{EX.}(T_{PEX})$ → TCF1 → $T_{EX}$ → CTLA-4, PD-1, TIM-3

IFNγ, IL-2, TNF, Target killing → Anti-PD-1 → Functional $T_{Effector}$
Cancers evolve many ways to suppress immune responses, including MDSCs, altered DCs, Treg, M2-like macrophages, others.
“Immune Checkpoint blockade”: Inhibit the inhibitors and increase anti-tumor immunity

CTLA-4 and PD-1 inhibit T cells by distinct mechanisms, thus anti-CLTA-4 and anti-PD-1 work to enhance T cells responses by different mechanisms.
Immune Checkpoint Blockade (ICB) Counteracts a Common Tumor Evasion Mechanism

• Many tumors express checkpoint ligands (e.g. PD-L1) and/or induce expression of checkpoint receptors on T cells (e.g. PD-1).

• Tumor-specific T cells often acquire an exhausted phenotype, which is in part characterized by upregulated expression of immune checkpoint molecules.

• ICBs are inhibitors of these inhibitors of anti-tumor T cell immunity and can reverse the exhausted phenotype.

• Approved ICB drugs are function blocking monoclonal antibodies specific for CTLA-4, PD-1, and PD-L1; clinical trials for others are in progress.

• Melanomas were the first tumors treated by ICBs, but now ICBs (mostly anti-PD-1 or anti-PD-L1) are used for many different tumor types.

• Many patients with metastatic tumors that were invariably fatal within months under older therapies have now survived for years on ICB therapy, with no evidence of tumor progression.
Challenges to Overcome in ICB Therapy

- Overall, only ~15% of ICB-treated patients respond to ICB therapy; why is not clear.
  - How to predict who will respond? (e.g. neoantigen burden)
  - How to convert non-responders to responders? (e.g. make tumors "hot")
  - Use of combinations of ICBs or ICB plus other types of therapies? (ICB + angiogenesis inhibitors)

- ~50% of ICB treated patients develop immune related adverse events IRAEs. (Autoimmunity is a predictable complication given that the checkpoint molecules’ normal functions are to prevent autoimmunity)
  - How do we predict who will develop IRAEs?
  - How can IRAEs be treated or avoided
  - What do IRAEs teach us about autoimmunity?

- Many responders will eventually suffer recurrences of tumor.
  - What are the mechanisms of developed resistance to ICB therapy?
  - How can this resistance be overcome?

From: June, Warshauser and Bluestone Nat Med 2017
Nivolumab and Relatlimab (anti-PD-1 + anti-LAG3 mAbs) – FDA approved to treat melanoma in 2022
Chimeric Antigen Receptor Design

Antigen Recognition:
Antibody-like single chain variable fragment (no MHC restriction)

CARs use signaling motifs from TCR complex and costimulatory receptors to activate the T cells

Chimeric antigen receptors (CARs) can make any T cell specific for a tumor antigen

Abbas, Lichtman, Pillai. Cellular and Molecular Immunology. Elsevier. 2021
FDA approved CAR-Ts or treatment of B cell-derived tumors: acute lymphocytic leukemias, B cell lymphomas (CD19); and multiple myeloma (targeting BCMA)
Limitations and Challenges of CAR-T Cell Therapy

- **Cytokine release syndrome** – many T cells respond to target antigen, activate macrophages
  - Requires anti-inflammatory therapy (e.g. anti-IL-6R)
  - Risk of long-term damage (especially brain)
- **Effectiveness against solid tumors** has been limited
  - Problem of T cells entering tumor site
- **Will tumors lose target antigen and develop resistance?**
- **Finding target antigens** specific for tumors, not normal cells
  - Target pairs of antigens dual specificity CARs?
- **Technical and regulatory challenges** of producing genetically modified CAR-T cells for each patient
  - Prospect of gene-edited “universal” CAR-T cells?
- **Exhaustion of transferred T cells**
  - Use CRISPR gene editing to delete PD-1 or genes regulating exhaustion from T cells
Future CAR-T Cell Therapies

Allen, G. M. et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science 2022


Jessica Hoppstädt and Alexandra K. Kieme, Signal Transduct Target Ther. 2023
Tumor Neoantigens Personalized Vaccines

Antibody-based Cancer Therapies

Anti-CD20 for B cell lymphoma (rituximab)

Anti-CD33: calicheamicin for AML (gemtuzumab)

Anti-EGFR for Colon CA (Cetuximab)

Anti-CD3/Anti-CD19 for B cell leukemia (Blinatumomab)